Company intelligence / Profile preview

Companion Medical

San Diego, California, United Statesmedtronicdiabetes.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Companion Medical developed InPen, the first FDA-cleared smart insulin pen system paired with a mobile app for diabetes management. The product was commercialized in the U.S., providing real-time dosing support and integration with glucose monitoring systems. The company was acquired by Medtronic in August 2020 and its technology continues under Medtronic's diabetes portfolio[1][3][7].

Therapeutic areas: Endocrinology
Modalities: DeviceDigital health solution (mobile app)Small molecule (insulin; not developed by company but used with device)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

InPen

Commercial

Indications: Diabetes

Partnerships

Dexcom (CGM data integration)One Drop (integrated blood glucose meter partnership)

Beyond the preview

Go deeper on Companion Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Companion Medical.

Explore the full profile